Challenges in Development of Nanoparticle-Based Therapeutics

Neil Desai

doi:10.1208/s12248-012-9339-4

journal article Mar 10, 2012

Challenges in Development of Nanoparticle-Based Therapeutics

Neil Desai

The AAPS Journal Vol. 14 No. 2 pp. 282-295 · Springer Science and Business Media LLC

View at Publisher Save 10.1208/s12248-012-9339-4

Topics

No keywords indexed for this article. Browse by subject →

References

96

[1]

Emerich DF, Thanos CG. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng. 2006;23(4):171–84. 10.1016/j.bioeng.2006.05.026

[2]

Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother Biomed Pharmacother. 2004;58(3):168–72. 10.1016/j.biopha.2004.01.007

[3]

Silva GA. Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS. BMC Neurosci. 2008;9 Suppl 3:S4. 10.1186/1471-2202-9-s3-s4

[4]

Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337–50. 10.1023/a:1025785505977

[5]

Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1–3):47–61. 10.1016/s0168-3659(01)00309-1

[6]

Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559–93. 10.1007/bf00047468

[7]

Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497–503.

[8]

Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (London, England). 2010;5(4):597–615. 10.2217/nnm.10.35

[9]

Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15(7–8):457–64. 10.1080/10611860701539584

[10]

Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8):876–85. 10.1016/j.addr.2007.08.044

[11]

Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–8. 10.1016/s0959-8049(01)00171-x

[12]

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–8. 10.1200/jco.1990.8.7.1263

[13]

van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19(2):125–41. 10.1023/a:1010618632738

[14]

Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton). 2005;10(3):317–20. 10.1111/j.1440-1797.2005.00389.x

[15]

Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392–7. 10.1038/sj.bjc.6604483

[16]

Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750–63. 10.1038/nrc903

[17]

Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688–701. 10.1038/nrc1958

[18]

Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57(4):637–51. 10.1016/j.addr.2004.10.007

[19]

Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel. 2004;17(5):433–41. 10.1093/protein/gzh055

[20]

Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003;91(1–2):115–22. 10.1016/s0168-3659(03)00240-2

[21]

Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release. 2009;140(2):166–73. 10.1016/j.jconrel.2009.08.011

[22]

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–24. 10.1158/1078-0432.ccr-05-1634

[23]

Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine—an overview. Fundam Clin Pharmacol. 2009;23(3):263–9. 10.1111/j.1472-8206.2009.00692.x

[24]

Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283–318. 10.1016/s0031-6997(24)01494-7

[25]

Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1–9. 10.1016/j.ejpb.2007.08.001

[26]

Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst. 1987;3(3):233–61.

[27]

Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–6.

[28]

Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607–12. 10.1073/pnas.95.8.4607

[29]

Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57–64. 10.1016/j.urolonc.2007.03.015

[30]

Moghimi SM. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett. 2003;540(1–3):241–4. 10.1016/s0014-5793(03)00273-4

[31]

Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463–78. 10.1016/s0163-7827(03)00033-x

[32]

Gessner A, Waicz R, Lieske A, Paulke B, Mader K, Muller RH. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm. 2000;196(2):245–9. 10.1016/s0378-5173(99)00432-9

[33]

Gigli I, Nelson Jr RA. Complement dependent immune phagocytosis. I. Requirements for C’1, C’4, C’2, C’3. Exp Cell Res. 1968;51(1):45–67. 10.1016/0014-4827(68)90158-4

[34]

Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res. 2006;23(6):1313–23. 10.1007/s11095-006-0069-0

[35]

Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380(6574):561–2. 10.1038/380561a0

[36]

Huang YF, Liu H, Xiong X, Chen Y, Tan W. Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. J Am Chem Soc. 2009;131(47):17328–34. 10.1021/ja907125t

[37]

Irvine DJ. Drug delivery: one nanoparticle, one kill. Nat Mater. 2011;10(5):342–3. 10.1038/nmat3014

[38]

Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials. 2011;32(11):3094–105. 10.1016/j.biomaterials.2010.12.054

[39]

O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9. 10.1093/annonc/mdh097

[40]

Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, et al. Role of complement activation in hypersensitivity reactions to Doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res. 2002;12(1–2):165–72. 10.1081/lpr-120004790

[41]

Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15(10):1527–34. 10.1093/annonc/mdh393

[42]

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24(12):903–20. 10.2165/00002018-200124120-00004

[43]

Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11(4):413–24. 10.2174/0929867043455909

[44]

Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58(4):1215–27. 10.1016/j.ijrobp.2003.10.057

[45]

Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315–20. 10.1073/pnas.0601755103

[46]

Rovira-Bru M, Thompson DH, Szleifer I. Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys J. 2002;83(5):2419–39. 10.1016/s0006-3495(02)75255-7

[47]

Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep. 2002;22(2):225–50. 10.1023/a:1020186505848

[48]

Zhu J, Xue J, Guo Z, Marchant RE. Vesicle size and stability of biomimetic liposomes from 3′-sulfo-Lewis a (SuLea) containing glycolipids. Colloids Surf B: Biointerfaces. 2007;58(2):242–9. 10.1016/j.colsurfb.2007.03.016

[49]

FDA. Guidance for Industry: Liposome Drug Products. 2002. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf .

[50]

Özcan I, Bouchemal K, Segura-Sánchez F, Abacı Ö, Özer Ö, Güneri T, et al. Effects of sterilization techniques on the PEGylated poly (γ-benzyl-l-glutamate) (PBLG) nanoparticles. Acta Pharm Sci. 2009;51:211–8.

Showing 50 of 96 references

Cited By

971

Alginate-driven nanotherapeutics in liver cancer: design, applications, and future perspectives

Tanvi Desai, Ekta Rawat · 2026

International Journal of Pharmaceut...

Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation

Vishal Kumar Deb, Abhishek Mukherjee · 2026

Frontiers in Bioengineering and Bio...

Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy

Hicham Wahnou, Riad El Kebbaj · 2025

Pharmaceutics

Antiproliferative activity of prepared Aloe vera leaf skin extract-loaded essential oil nanoemulsions using Box-Behnken design

Liana Parseghian, Hossein Behboudi · 2025

Industrial Crops and Products

A review on targeting tunable nanocarrier interaction, physiochemical properties, and futuristic nanocarrier

Sonia Pandey, Shrikant Joshi · 2025

Biochimica et Biophysica Acta (BBA)...

Recent Advances in Green Metallic Nanoparticles for Enhanced Drug Delivery in Photodynamic Therapy: A Therapeutic Approach

Alexander Chota, Blassan P. George · 2023

International Journal of Molecular...

Low-density lipoprotein: a versatile nanoscale platform for targeted delivery

Luyao Dai, Shuaijun Li · 2023

Nanoscale Advances

Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

Sayali Dighe, Sunil Jog · 2023

Pharmaceutics

Tumor-derived systems as novel biomedical tools—turning the enemy into an ally

Nimeet Desai, Pratik Katare · 2023

Biomaterials Research

Advances in Lung Cancer Treatment Using Nanomedicines

Akshansh Sharma, Devanshi Shambhwani · 2022

ACS Omega

Application of Green Gold Nanoparticles in Cancer Therapy and Diagnosis

Saman Sargazi, Ushna Laraib · 2022

Nanomaterials

Formulation, process, and storage strategies for lyophilizates of lipophilic nanoparticulate systems established based on the two models paliperidone palmitate and solid lipid nanoparticles

Eduard Trenkenschuh, Ula Savšek · 2021

International Journal of Pharmaceut...

Natural product-based nanoformulations for cancer therapy: Opportunities and challenges

Dharambir Kashyap, Hardeep Singh Tuli · 2021

Seminars in Cancer Biology

Albumin nanocarriers for pulmonary drug delivery: An attractive approach

Monica Joshi, Mangal Nagarsenkar · 2020

Journal of Drug Delivery Science an...

Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Mengfei Guo, Feng Wu · 2019

Science Translational Medicine

Large‐Scale Synthesis and Medical Applications of Uniform‐Sized Metal Oxide Nanoparticles

Hyek Jin Kwon, Kwangsoo Shin · 2018

Advanced Materials

Programmable Nano–Bio Interfaces for Functional Biointegrated Devices

Pingqiang Cai, Wan Ru Leow · 2017

Advanced Materials

The battle of “nano” paclitaxel

Alexandros Marios Sofias, Michael Dunne · 2017

Advanced Drug Delivery Reviews

Bovine milk-derived exosomes for drug delivery

Radha Munagala, Farrukh Aqil · 2016

Cancer Letters

Biocompatibility and internalization of molecularly imprinted nanoparticles

Francesco Canfarotta, Alicia Waters · 2016

Nano Research

Metrics

971

Citations

96

References

Details

Published: Mar 10, 2012
Vol/Issue: 14(2)
Pages: 282-295
License: View

Authors

N

Neil Desai

Cite This Article

Neil Desai (2012). Challenges in Development of Nanoparticle-Based Therapeutics. The AAPS Journal, 14(2), 282-295. https://doi.org/10.1208/s12248-012-9339-4

Challenges in Development of Nanoparticle-Based Therapeutics

You May Also Like